Characteristic of the study population
| Ondansetron (n = 18) | Placebo (n = 18) | |
|---|---|---|
| Hep C, hepatitis C virus; ALT, alanine aminotransferase. | ||
| There were no significant differences between the groups. | ||
| Sex | 10F/8M | 15F/3M |
| Age (y) | 48.2 (8.3) | 52.5 (11.4) |
| Body weight (kg) | 63.5 (10.5) | 62.8 (10.2) |
| Height (cm) | 160 (20.6) | 162 (7.3) |
| ALT (U/l) | 72.8 (58.0) | 64.5 (50.9) |
| Hep C viral load (106 copies/ml) | 11.1 (10.6) | 7.0 (7.5) |
| METAVIR score | ||
| Activity index | 1.2 (0.4) | 1.2 (0.9) |
| Fibrosis index | 1.2 (0.5) | 1.1 (0.4) |